What is a stock summary page? Click here for an overview.
Business Description
Marinus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US56854Q1013
Compare
Compare
Traded in other countries / regions
MRNS.USA0JYL.UKMRNS.Mexico61Y.Germany Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2014-07-31Description
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.75 | |||||
| Equity-to-Asset | -1.05 | |||||
| Debt-to-Equity | -0.84 | |||||
| Debt-to-EBITDA | -0.46 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -20.09 | |||||
| Beneish M-Score | -3.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 109.2 | |||||
| 3-Year EBITDA Growth Rate | 1.7 | |||||
| 3-Year EPS without NRI Growth Rate | 2.1 | |||||
| 3-Year FCF Growth Rate | 0.5 | |||||
| 3-Year Book Growth Rate | -56.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 55.12 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 28.42 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.95 | |||||
| 9-Day RSI | 77.84 | |||||
| 14-Day RSI | 70.4 | |||||
| 3-1 Month Momentum % | 55.47 | |||||
| 6-1 Month Momentum % | -55.98 | |||||
| 12-1 Month Momentum % | -94.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | |||||
| Quick Ratio | 1.47 | |||||
| Cash Ratio | 1.22 | |||||
| Days Inventory | 531.73 | |||||
| Days Sales Outstanding | 43.77 | |||||
| Days Payable | 535.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.3 | |||||
| Shareholder Yield % | 26.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.17 | |||||
| Operating Margin % | -389.7 | |||||
| Net Margin % | -446.49 | |||||
| FCF Margin % | -364.67 | |||||
| ROA % | -106.47 | |||||
| ROIC % | -659.49 | |||||
| 3-Year ROIIC % | -467.76 | |||||
| ROC (Joel Greenblatt) % | -3071.01 | |||||
| ROCE % | -129.75 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1 | |||||
| EV-to-EBIT | -0.36 | |||||
| EV-to-EBITDA | -0.36 | |||||
| EV-to-Revenue | 1.4 | |||||
| EV-to-Forward-Revenue | 0.71 | |||||
| EV-to-FCF | -0.39 | |||||
| Price-to-GF-Value | 0.07 | |||||
| Earnings Yield (Greenblatt) % | -277.78 | |||||
| FCF Yield % | -377.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRNS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Marinus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 31.466 | ||
| EPS (TTM) ($) | -2.47 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.05 | ||
| Volatility % | 144.67 | ||
| 14-Day RSI | 70.4 | ||
| 14-Day ATR ($) | 0.011892 | ||
| 20-Day SMA ($) | 0.54395 | ||
| 12-1 Month Momentum % | -94.68 | ||
| 52-Week Range ($) | 0.2202 - 10.5 | ||
| Shares Outstanding (Mil) | 55.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Marinus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Marinus Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Marinus Pharmaceuticals Inc Frequently Asked Questions
What is Marinus Pharmaceuticals Inc(MRNS)'s stock price today?
The current price of MRNS is $0.55. The 52 week high of MRNS is $10.50 and 52 week low is $0.22.
When is next earnings date of Marinus Pharmaceuticals Inc(MRNS)?
The next earnings date of Marinus Pharmaceuticals Inc(MRNS) is 2025-05-08 Est..
Does Marinus Pharmaceuticals Inc(MRNS) pay dividends? If so, how much?
Marinus Pharmaceuticals Inc(MRNS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers